Welcome to our dedicated page for GE HealthCare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on GE HealthCare Technologies stock.
GE HealthCare Technologies Inc. develops medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions for healthcare providers. News about GEHC commonly covers its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions businesses, including MR, CT, molecular imaging, women’s health, X-ray, ultrasound, image-guided solutions, and enterprise imaging.
Company updates also address quarterly results, orders and backlog, operational changes, acquisitions such as Intelerad, and product or collaboration announcements. Recurring themes include next-generation SIGNA MR systems, helium-free MR technology, bkActiv intraoperative ultrasound integration, AI-powered mammography tools, and the mangaciclanol MRI contrast-agent pipeline.
GE HealthCare (Nasdaq: GEHC) announced U.S. FDA 510(k) clearance and CE Mark for Allia Moveo on February 2, 2026, and reported the first global installation at Hôpital Marie-Lannelongue in France and the first U.S. installation at Baylor St. Luke’s Medical Center.
Allia Moveo is a compact, cable-free C-arm platform with AI-driven 3D imaging tools (CleaRecon DLi, Motion Freeze, Metallic Artifact Reduction) and augmented guidance designed to improve mobility, image clarity, and workflow in complex interventional procedures.
GE HealthCare (Nasdaq: GEHC) announced it received an unsolicited mini-tender offer from Potemkin Limited to buy up to 100,000 shares of GE HealthCare common stock for $54.20 per share in cash.
The offer price is approximately 34.77% below the $83.09 closing price on December 8, 2025. GE HealthCare does not endorse the offer, says Potemkin is not affiliated with the company, and recommends stockholders do not tender because the price is well below market and the offer is subject to numerous conditions.
The offer currently expires at 5:00 p.m. ET on June 9, 2026; shareholders who have already tendered may withdraw shares within 14 days after delivery of the acceptance form, per the offer documents.
GE HealthCare (Nasdaq: GEHC) will report its fourth quarter and full year 2025 financial results before market open on February 4, 2026.
The GE HealthCare management team will host a live conference call and webcast on February 4, 2026 at 8:30 a.m. ET / 7:30 a.m. CT. The earnings release, accompanying financial information, and a replay of the webcast will be posted at https://investor.gehealthcare.com/news-events/events.
GE HealthCare (Nasdaq: GEHC) said members of its management team will present at the JP Morgan 44th Annual Healthcare Conference in San Francisco on January 13, 2026 at 10:30 a.m. PT / 1:30 p.m. ET. A live webcast will be available on the company investor website at the scheduled time.
GE HealthCare (Nasdaq: GEHC) will supply more than 300 CT scanners to public hospitals across all 38 provinces of Indonesia under the multi‑year SIHREN program, targeting installation by 2028 to expand diagnostic access for more than 280 million Indonesians.
The competitively awarded contract follows World Bank procurement rules and supports NCD management, maternal health and pandemic resilience. GE HealthCare is expanding local capability via a Bogor production facility, recent awards for 10 1.5T MR systems (early 2025), and the RITE training hub (2024) to build workforce skills and technology transfer.
GE HealthCare (Nasdaq: GEHC) and Mayo Clinic launched GEMINI-RT, a research collaboration announced on December 3, 2025 to advance personalized radiation therapy by integrating imaging, AI, and patient monitoring across the cancer care continuum.
The initiative focuses on four pillars: Automation, Predictive Oncology, Multi‑modal Therapies, and Connected Care, and will be based at Mayo Clinic’s Rochester campus. GEMINI-RT aims to streamline data-driven planning, reduce clinician burden, model individual patient journeys, and explore combining radiation with targeted therapies and home monitoring.
University of Rochester Medical Center and GE HealthCare (Nasdaq: GEHC) launched a seven-year Care Alliance on December 3, 2025 to standardize imaging and monitoring across UR Medicine.
The program includes upgrades and new MRI, Aurora SPECT/CT, dual-energy CT, LOGIQ E10 ultrasound, on-device AI, a Continuum+ software upgrade path, plans for an on-site cyclotron to produce radiopharmaceutical tracers, and system-wide Carescape ONE monitoring powered by Carescape Canvas.
GE HealthCare (Nasdaq: GEHC) announced expanded collaboration with NVIDIA at RSNA 2025 to embed NVIDIA accelerated computing across CT, MRI, ultrasound, cardiac, and mammography solutions.
Key highlights include Photonova Spectra PCCT (510(k) pending) claiming up to 50x more data throughput, SIGNA Bolt and SIGNA Sprint MRI platforms using NVIDIA GPU-accelerated reconstruction, Pristina Recon DL for 3D mammography, and Vivid Pioneer ultrasound with dual professional NVIDIA GPUs. Early-stage autonomous X-ray and ultrasound concepts are being explored with NVIDIA Isaac and Holoscan.
GE HealthCare (Nasdaq: GEHC) unveiled Allia Moveo, a compact, cable-free C-arm image-guiding solution for the interventional suite designed to increase mobility, patient access and workflow efficiency. The system features a slim, wide-bore C-arm intended to enable cone beam CT (CBCT) for a broader patient range, ergonomic controls accessible from nearly any position, AI-powered and augmented guidance tools, and SmartMove to reposition and restore the C-arm at the press of a button. Allia Moveo supports multi-modality integrations and is FDA 510(k) pending. Availability may vary by region; GE HealthCare will showcase the platform at RSNA 2025 (booth #7334).
GE HealthCare (Nasdaq: GEHC) will present at RSNA 2025 on November 30, 2025, showcasing more than 40 technology innovations across imaging devices, radiopharmaceuticals, cloud and AI solutions.
Key disclosures include $3B invested in R&D since 2022; the FDA-approved PET MPI agent Flyrcado (flurpiridaz F 18) with CMS traditional pass-through effective Apr 1, 2025; Photonova Spectra photon-counting CT (510(k) pending); next‑gen SIGNA MRI systems (510(k) pending); and a claim of 100 FDA-authorized AI-enabled solutions.